Hits, Misses & Key Firsts For EMA’s PRIME Scheme

 
• By Neena Brizmohun

The rate at which investigational drugs were accepted onto the European Medicines Agency’s priority medicines scheme dropped in 2021. Meanwhile, more much-needed treatments that had been developed under the scheme went on to win EU marketing approval.

Antigen Recepto
Advanced therapies are among the candidates on the PRIME scheme • Source: Alamy

The number of investigational drugs that the European Medicines Agency accepted onto PRIME, its scheme for medicines that have the potential to address unmet medical needs, dropped sharply in 2021. Just 14 products secured a much-coveted place on the scheme.

The rate at which products were being accepted onto PRIME had been rising gradually in recent years, from 23% of applications in 2018 to 33% in 2020, when 20 drugs were

Meanwhile, medicines developed under the scheme continued to win pan-EU marketing

More from Europe

More from Geography

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.